L.V. Prasad Eye Institute
13 clinical trials · Sponsor
◉ Watch L.V. Prasad Eye Institute
| Record | Firm | Date |
|---|---|---|
| To Evaluate the Clinical Safety and Efficacy of Limbal Stem Cell for Treatment of Superficial Corneal Pathologies". (NCT04932629) | L.V. Prasad Eye Institute | 2021-07-01 |
| CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops (NCT04843839) | L.V. Prasad Eye Institute | 2020-12-15 |
| SEED-LVPEI Myopia Study (NCT04618510) | L.V. Prasad Eye Institute | 2020-12-11 |
| Six-months Versus Nine-months ATT for Ocular TB (NCT06613919) | L.V. Prasad Eye Institute | 2020-01-01 |
| Ologen® Collagen Matrix Versus Mitomycin-C in Patients With Juvenile-onset Open Angle Glaucoma (NCT03548805) | L.V. Prasad Eye Institute | 2018-08-16 |
| Ologen® Collagen Matrix in Patients With Primary Congenital Glaucoma Undergoing Trabeculectomy (NCT03541551) | L.V. Prasad Eye Institute | 2018-07-13 |
Track L.V. Prasad Eye Institute automatically
Every clearance here is in the API, with alerts when new ones post.